pentamethylmelamine has been researched along with cb 10375 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Abel, G; Graham, MA; Judson, IR; Rutty, CJ | 1 |
| Abel, G; Goddard, PM; Harrap, KR; Judson, IR; Newell, DR; Rutty, CJ | 1 |
3 other study(ies) available for pentamethylmelamine and cb 10375
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
Topics: Altretamine; Animals; Blood Proteins; Blood-Brain Barrier; Brain; Kinetics; Male; Mice; Mice, Inbred BALB C; Protein Binding; Triazines | 1986 |
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Topics: Altretamine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Plasmacytoma; Rats; Rats, Inbred Strains; Solubility; Triazines | 1986 |